Literature DB >> 25198301

Long-term result of cementless femoral stem in avascular necrosis of the hip.

Kin W Cheung1, Kwok H Chiu, Kwong Y Chung.   

Abstract

Avascular necrosis (AVN) of the hip may have extensive involvement of the proximal femur which may affect boney ingrowth into cementless femoral stems. From 1994 to 2004, 182 total hip arthroplasties (in 144 patients, 117 AVN hips and 65 non-AVN hips) were performed using hydroxyapatite coated femoral stems. All patients were followed up prospectively. Mean age was 51 years and mean follow-up 14.7 years (range 9.7-19.1 years). Four stems were revised because of aseptic loosening, 3 in AVN group and 1 in non-AVN group. The overall mechanical failure rate was 2.2%, the mechanical failure rate in AVN and non-AVN group was 2.6% and 1.5% respectively (p = 1). The 19.1 year survival using revision for aseptic loosening as an endpoint for AVN and non-AVN patients were 97.1% and 96.2% respectively (p = 0.654). Stable boney ingrowth was present in 99.5% hips. This study represents 1 of the largest series reporting the long-term follow-up of the use of cementless femoral stems in treating AVN of the hip. We report excellent long-term survival of cementless total hip arthroplasty used in managing AVN of the hip and is comparable to that seen in non-AVN total hip arthroplasty.

Entities:  

Mesh:

Year:  2014        PMID: 25198301     DOI: 10.5301/hipint.5000187

Source DB:  PubMed          Journal:  Hip Int        ISSN: 1120-7000            Impact factor:   2.135


  2 in total

1.  Total hip arthroplasty with dual mobility cup in osteonecrosis of the femoral head in young patients: over ten years of follow-up.

Authors:  Pierre Martz; Alexandre Maczynski; Sebastien Elsair; Ludovic Labattut; Brice Viard; Emmanuel Baulot
Journal:  Int Orthop       Date:  2016-11-25       Impact factor: 3.075

2.  Short stem total hip arthroplasty for osteonecrosis of the femoral head in patients 60 years or younger: a 3- to 10-year follow-up study.

Authors:  Antonio Capone; Fabrizio Bienati; Stefania Torchia; Daniele Podda; Giuseppe Marongiu
Journal:  BMC Musculoskelet Disord       Date:  2017-07-17       Impact factor: 2.362

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.